Congratulations da. You make us proud every day!

Once a wise person said, you don't get old, you get aged. #Dr.Duong

The 4 Current Treatment Algorithms for myeloma shown at #IMWG19 #MyelomaVR #mmsm Yelak Biru Jack Aiello @MyelomaTeacher - Cindy Chmielewski Mike Thompson, MD, PhD, FASCO International Myeloma Foundation Mayo Myeloma

Honored to be appointed to the academic rank of Assistant Professor of Oncology and Medicine by the Mayo Clinic College of Medicine and Science. Thank You Mayo Clinic Mayo Clinic Hematology-Oncology Fellowship Mayo Clinic Med Ed Mayo Clinic Comprehensive Cancer Center Mayo Clinic Internal Medicine Residency Rochester

Almost 20 years ago an Indian drug company, Cipla, lead the way. And now even expensive drugs like imitanib for the treatment of killer diseases like chronic myeloid leukemia can be accessed for free in poor countries like India and Nepal. nyti.ms/2XsZWi5

Only 2 weeks to #ESMOBreast25, one of my favorite conferences. Dozens of impactful abstracts to be presented, alongside great educational presentations to put the new data into context. Here’s a personal selection of 10 key presentations to follow during the conference. #bcsm

Check out this recent Annals of Oncology #ctDNA review and meta-analysis👉Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors. 👉pubmed.ncbi.nlm.nih.gov/40187491/

In JTO & JTO CRR #BRAF-mutated #NSCLC: bit.ly/JTO_BRAF 📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows: ➖ Similar OS outcomes ➖ PD-L1 status & gender influence prognosis 🎯 Personalization > one-size-fits-all LungCancerRx 🫁💊 OncoDaily Oncology Brothers

🚨🔥OncoAlert Hot Off The Press 1/2 U.S. FDA granted #accelerated approval to #Telisotuzumab-Vedotin for: ⭐️ #Patients with advanced non-squamous non-small cell #LungCancer AND: ✅#High #cMet overexpression ✅Received a prior systemic therapy 👇🏻 fda.gov/drugs/resource…

🔥🚨OncoAlert Hot Off The Press Big #NewsRelease by Summit Therapeutics in time with #ASCO25 Results from the #HARMONi Phase III global trial evaluating: #Ivonescimab + #Chemo vs #Chemo in pts with advanced #EGFR+ #NSCLC after progression on 3rd gen TKI: ⭐️Statistically significant &

Early data from Roxana Dronca, M.D.’s Cancer Care Beyond Walls trial show home-based cancer therapy is feasible & safe. Pts. reported excellent experiences, with majority preferring home-based treatment. Ongoing accrual will further evaluate clinical outcomes & cost implications. #ASCO25

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

🔥🚨OncoAlert Hot Off The Press Just published NEJM in conjunction with presentation ASCO #ASCO25 #OverallSurvival Results of #Checkmate816 phase 3 trial of: #Neoadjuvant #Nivolumab + Chemo vs Chemo in stage IB-IIIA Non-Small-Cell #LungCancer ✅#OS: HR: 0.72 (5-year: 65.4%

Grateful for the opportunity to present my poster in early stage triple negative breast cancer at #ASCO25 Huge thanks to my incredible mentors and senior authors for their guidance, support, and inspiration every step of the way. 🙏 Roberto Leon-Ferre Matthew Goetz Dr. Giridhar.

Honored to have presented 1 oral abstract and presented/co-authored 4 posters at #ASCO25 —an incredible experience representing the impactful research led by Mayo Clinic Comprehensive Cancer Center . Grateful to my collaborators for their partnership and support.

Hematology/Oncology Resident Sarah Premji, MD discusses her #ASCO25 abstract: "Estrogen receptor expression in residual #BreastCancer following neoadjuvant chemotherapy." Read the abstract here: ascopubs.org/doi/10.1200/JC…

⭐️INCREDIBLE #ASCO25 is over but ASCO’s GREAT mission CONTINUES. From one great Eric J. Small, MD, FASCO theme to another: ✅Driving #Knowledge to #Action. Building a #BetterFuture ⬇️ ✅The #Science & Practice of #Translation: Improving #Cancer Outcomes #Worldwide

Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. Yi Lin Mayo Myeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-g…

Check out this recent review on the management of metastatic hormone receptor-positive #BreastCancer Beyond CDK4/6 Inhibitors. 🔓pubmed.ncbi.nlm.nih.gov/40434676/ ✍️Antonio Giordano, MD PhD Erica Mayer Sara Tolaney Paolo Tarantino Ilana Schlam @AnaGarridoCastro